Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

MMK reduced steel production and sales by 14% in 2022

2/10/23 MAGN

Sitronics Group will orbit dozens of satellites in 2023 and set sail the first hydrogen-powered ship

2/10/23 AFKS

UAC intends to develop a unified system of after-sales service of Russian aircraft in India

2/10/23 UNAC

Developer Samolet sold 32% more real estate in 2022

2/10/23 SMLT

Profit of Samolet for 2022 according to management accounts increased by 57%

2/10/23 SMLT

Alteryx's loss doubled in 2022

2/10/23 AYX

Qualys reported for 2022

2/10/23 QLYS

PayPal's profit in 2022 decreased by 42%

2/10/23 PYPL

Noventiq will enter the Nasdaq via SPAC

2/10/23 SFTL

The Nike announced a quarterly dividend

2/9/23 NKE